Details of the Drug

General Information of Drug (ID: DMG48WN)

Drug Name
G0-203-2c
Indication
Disease Entry ICD 11 Status REF
Pancreatic cancer 2C10 Phase 1/2 [1]
Acute myeloid leukaemia 2A60 Phase 1 [2]
Cross-matching ID
TTD ID
D04WHM
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Mucin-1 (MUC1) TTBHFYQ MUC1_HUMAN Modulator [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Pancreatic cancer
ICD Disease Classification 2C10
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Mucin-1 (MUC1) DTT MUC1 4.59E-01 -0.07 -0.41
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02204085) A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Genus 0ncology.
3 Clinical pipeline report, company report or official report of Genus Oncology.